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J.S. Viana, H. Vieira, C. Bento, S. Neves, C. Seco, and A.L. Furtado
FAMILIAL amyloid polyneuropathy (FAP) is a geneticdisorder inevitably lethal without liver transplantation.
This procedure has been performed for FAP since 19901
and this disease is now, by far, the most frequent metabolic
indication for liver transplantation, with more than 700
patients having undergone transplantation worldwide. In
the last years, results improved significantly, and FAP
Met30 1-year survival rates reached 90% to 98%.
Because these patients had no liver insufficiency, their
livers have been used as grafts in transplantation of other
patients, since October 1995, in the so-called “domino” or
sequential liver transplantation.2
PURPOSE
The purpose of this study was to evaluate changes in
intraoperative management of FAP Met30 patients during
liver transplantation in three successive time periods from
1992 to 2002, and to compare these changes with the
intraoperative management of non-FAP adult patients who
underwent transplantation in similar periods.
PATIENTS
This study included all 140 patients with FAP Met30 submitted to
first liver transplantation in our institution from October 1992 to
May 2002. Group IA included 49 patients who underwent trans-
plantation from 1992 to 1996, Group IIA included 44 patients who
underwent transplantation from 1997 to 1999, and Group IIIA
included 47 patients who underwent transplantation from 2000 to
2002. We used as control the 184 non-FAP patients submitted to
first liver transplantation in our institution to 18 years of age or
older, divided into Group IB (1992 to 1996, 58 patients), Group IIB
(1997 to 1999, 64 patients), and Group IIIB (2000 to 2002, 62
patients).
Within the patients with FAP no group differences were ob-
served concerning age, sex, weight, and duration of clinical disease
pretransplantation, although the outcomes were different with
1-year actuarial survival rates of 79.6% in Group IA, 95.5% in
Group IIA, and 98.0% in Group IIIA (P .010). Groups also were
different concerning donation for domino transplantation as the
livers of 5 Group I patients (10%), 19 Group IIA patients (43%),
and 27 Group IIB patients (57%) were harvested as grafts for other
patients (P  .001).
METHODS
The groups were compared with nonparametric tests (Mann-
Whitney U test, Kruskal-Wallis test, or chi-square test as appropri-
ate). Kaplan-Meier curves were compared using Cox regression.
Data as mean  SD.
RESULTS
The anesthetic technique was similar for patients with and
without FAP and during all study periods: induction with
thiopental, succinylcholine, and fentanyl, maintenance with
isoflurane (in oxygen/air), fentanyl, and vecuronium
or pancuronium, depending on the heart rate. Immunosup-
pression also was the same: methylprednisolone and aza-
thioprine in the operating room, and cyclosporine exclu-
sively in the postoperative period. In both FAP and
non-FAP, a progressive decrease was observed in use of
blood products. For FAP, red blood cells (RBC), needs
decreased from 5.8  10.7 U per transplantation in 1992 to
1996 to 4.2 7.4 in 1997 to 1999 to 2.0 2.0 in 2000 to 2002
(P  .013). In patients without FAP, the use of decreased
RBC felt from 12.5  11.2 U per transplantation in 1992 to
1996, to 14.4  5.5 in 1997 to 1999 to 5.5  5.3 in 2000 to
2002 (P  .001). Greater reductions were observed in the
use of fresh frozen plasma (P  .001 either in FAP or
non-FAP), and of platelet concentrates (P  .046 in FAP
and P  .001 in non-FAP). During the last years, albumin
was less frequently employed as a plasma expander, with an
increase in synthetic solutions, particularly hydroxyethyl-
starches.
Major differences were observed in vasoactive drugs to
support circulation; phenylephrine infusions were used in
12.2% of FAP transplantation in 1992 to 1996, 54.5% in
1997 to 1999, and 53.5% in 2000 to 2002 (P  .001).
Low-dose dopamine (3 g/kg/min) was used in all pa-
tients. Rates equal or higher than 10 g/kg/min were used
only in 16.3% of Group IA, 8.5% of Group IIA, and 8.5%
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of Group IIIA (P  not significant). No statistical differ-
ences were observed among non-FAP patients concerning
the use of vasoactive drugs. High-dose aprotinin (Hammer-
smith regimen) was employed only in the initial 8 (5.7%)
FAP transplantation. For non-FAP patients, aprotinin
which remained the rule for those with coagulopathies and
portal hypertension, was used in 79.2% of transplantation.
Veno-venous porto-caval-axillary bypass with a Biomedi-
cus pump was used in the initial two patients with FAP and
the initial 10 patients without FAP before the piggyback
technique became the rule. Donation to domino liver
transplantation imposed the interruption of the inferior
vena cava for patients with FAP and the return to the
original technique with bypass. In non-FAP patients, bypass
was used occasionally (24.7%) to decompress the venous
pressure in the surgical field.
The policy of previous pacemaker insertion in patients
with FAP was progressively more defensive. Initially, the
rules for pacemaker insertion in patients with FAP waiting
liver transplantation were similar to those applied to the
general population. Since 1995, the indications include
Classes I and II of the classification of the American
College of Cardiology and the American Heart Association,
resulting in 18% of patients with FAP with an intracavitary
pacemaker on the date of transplantation. Recently, preop-
erative pacemaker insertion was extended to any patient
with FAP with a conduction disturbance (even intermittent
and asymptomatic) or also history of syncope (even when a
cardiac cause was not proved). Overall, 23 patients with
FAP (16.1%) had a permanent pacemaker on the date of
transplantation. The tendency to earlier transplantation
counteracted the increased indications for a pacemaker, the
percentage of patients who underwent transplantation with
a pacemaker has decreased over time. In control (non-
FAP) patients, no one had a pacemaker on the date of
transplantation.
DISCUSSION
The major differences in intraoperative management of
patients with FAP Met30 for liver transplantation were a
progressive increase in the use of pure vasoconstrictors (our
choice was phenylephrine), and a progressive decrease in
the consumption of blood products (including albumin)
with a compensatory increase in synthetic plasma expand-
ers. The reduced consumption of blood products, which
may represent better surgical technique or low values of
transfusional triggers, was similar to non-FAP patients. The
tendency to less extensive use of albumin, which reflects the
general trend of the 1990s, also was common to FAP and
non-FAP patients. On the other hand, the changes in
vasoactive drugs deserve special comment because they
were specific for patients with FAP. When liver transplan-
tation started in FAP, it was known that these patients
exhibited remarkable hemodynamic instability during anes-
thesia and surgery,3 their cardiac risk was soon recognized
to be an important factor in transplantation outcome.4,5
The causes for hemodynamic instability were not com-
pletely clear. The few available reports laid particular
emphasis on rhythm disturbances.3 The increased use of
vasoconstrictors is a consequence of the understanding that
low vascular resistance was the main intraoperative prob-
lem4–6 and that these drugs are effective to restore arterial
pressures.4–6 Obviously, their increased use in patients with
FAP had no parallel in non-FAP patients because deregu-
lation of the autonomic circulatory control was not of
special significance in FAP.
On the contrary, the use of dopamine did not increase in
FAP and, when used, the tendency was not to use high
doses. This practice was a consequence of preliminary
reports that dopamine use in patients with FAP did not
increase vascular resistance, but rather decreased its fre-
quently being ineffective to support the circulation.5,7
To what extent the changes in intraoperative manage-
ment have played a role in improving the results of FAP
liver transplantation, is a question with no easy answer. It is
recognized that the experience achieved in liver transplan-
tation for FAP has increased the safety in anesthetic
management of these patients, independent of the kind of
surgery and the environment, but the increased posttrans-
plantation survival is probably more related to better pa-
tient selection than differences in intraoperative manage-
ment.
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